Therefore, through triggering GPCRs, SCFAs can improve insulin sensitivity, stop the growth of white adipose tissue, and lower inflammation, all of which lead to an improvement in T2D patients’ glucose metabolism. Here, INS is linked to type 2 diabetes mellitus.